Enhancing anti-tumor immunity through TIGIT blockade and tumor-directed targeting in pancreatic cancer
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115653 ↗At a glance
Journal article in International Immunopharmacology, 2025. Written by Yun Jung Um and 15 co-authors. Institution: College of Pharmacy, Ajou University, 206 World Cup-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 16499, Republic of Korea. Major MEDLINE topics: Receptors, Immunologic, Pancreatic Neoplasms, Antibodies, Bispecific, Carcinoma, Pancreatic Ductal. Cited 4 times so far (Crossref); 70 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: National Research Foundation of Korea.
Abstract (original language)
Pancreatic ductal adenocarcinoma (PDAC) exhibits profound resistance to immune checkpoint blockade, driven by a dense stroma, low immunogenicity, and an immunosuppressive tumor microenvironment. T cell immunoreceptor with Ig and ITIM domain (TIGIT) is an inhibitory receptor expressed on tumor-infiltrating lymphocytes and contributes to immune dysfunction in PDAC through its interaction with PVR. To selectively modulate the TIGIT axis within the tumor microenvironment, we developed a bispecific antibody (chi2B5×4F11) that targets TIGIT while anchoring to CUB domain-containing protein 1 (CDCP1), thereby enabling spatially confined immune activation in CDCP1-positive tumor niches. Functional characterization using in vitro NK-92 cell assays and in vivo studies using a humanized mouse model engrafted with CDCP1+ PANC-1 cells demonstrated the efficacy of these antibodies. Parental chi4F11 effectively blocked the TIGIT-PVR axis, restoring AKT-FOXO1 signaling without altering CD226 expression. Chi2B5×4F11 further enhanced NK-92 cell-mediated cytotoxicity and induced the release of pro-inflammatory cytokines in vitro. In vivo, treatment with chi2B5×4F11 reduced the proportion of TIGIT+ circulating immune subsets within the CD226+ compartment, suggesting functional restoration of co-stimulatory signaling. These findings highlight TIGIT as a crucial therapeutic target and suggest a strategy to overcome the immune resistance of pancreatic cancer.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- College of Pharmacy, Ajou University, 206 World Cup-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 16499, Republic of Korea.
- School of Medicine, Ajou University, 206 World Cup-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 16499, Republic of Korea.
- Department of Molecular Science and Technology, Ajou University, 206 World Cup-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 16499, Republic of Korea.
- Orient Genia, 322 Galmachi-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do 13201, Republic of Korea.
- Novelty Nobility, 227 Unjung-ro, Seongnam-si, Gyeonggi-do 13477, Republic of Korea.
- Target Link Therapeutics, Inc., Seoul 04545, Republic of Korea.
Funding
- National Research Foundation of Korea
Cite
APA
Um, Y. J., Kwak, D., Kim, S. Y., Chang, H. J., Yum, S. H., Hwang, J., Kim, J. E., Jung, J. Y., Hong, S. H., Park, S., Lee, J., Kim, S. K., Oh, Y. S., Seo, M. D., Kim, M. R., & Park, S. G. (2025). Enhancing anti-tumor immunity through TIGIT blockade and tumor-directed targeting in pancreatic cancer. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115653
Vancouver
Um YJ, Kwak D, Kim SY, Chang HJ, Yum SH, Hwang J, et al. Enhancing anti-tumor immunity through TIGIT blockade and tumor-directed targeting in pancreatic cancer. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115653
BibTeX
@article{Um2025,
author = {Um, Yun Jung and Kwak, Dongwook and Kim, Seok Yung and Chang, Hye Jin and Yum, Sun Hyung and Hwang, Junsik and Kim, Ji-Eun and Jung, Ji Yun and Hong, Shin Hee and Park, Sohyeon and Lee, Jihye and Kim, Seon Ki and Oh, Young Sun and Seo, Min-Duk and Kim, Mi Ran and Park, Sang Gyu},
title = {Enhancing anti-tumor immunity through TIGIT blockade and tumor-directed targeting in pancreatic cancer},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115653}
}
EUVIMED